GlobeNewswire PharmaceuticalsCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:00:00·⟳ 抓取 19:01:17·⚡ 决策 09-01 19:39:57 +38m40s·56.0 天前
Syndax宣布参加9月两场投资者会议
正文已经足以判断这是常规投资者会议参与公告，不含新增业务、临床、监管或财务信息；继续查行情、先例或供应链不会改变不交易结论。
📄 原文GlobeNewswire Pharmaceuticals↗ 原文
Syndax Announces Participation in September Investor Conferences
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutica…
不做 Syndax Pharmaceuticals（SNDX.US）
仅为常规投资者会议参与公告，没有新增基本面、监管、临床或财务信息，无法形成方向性交易 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
该消息的事实仅是Syndax Pharmaceuticals管理层将在两场9月投资者会议进行炉边谈话并提供 webcast。会议可能带来后续信息披露，但当前公告没有新增数据、审批、试验结果、销售或指引变化，因此没有可量化的预期差和正负方向，不构成交易催化。
🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗
主要风险
- 后续会议上若披露新的临床、商业化或指引信息，需要按届时新事实重新评估。
先例如何影响了这次决策
对本次决策的影响:先例研究不会改变本次结论，因为事件缺少新增可交易事实。
方向:未使用先例；常规会议日程公告本身不具备方向性，历史价格反应不会改变不交易判断。
涨幅量级:无可校准幅度。
形态:不适用。
原文全文
展开原文 · 1,552 字
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Citi 2026 Biopharma Back to School Conference
in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference
in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at
www.syndax.com
, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
LinkedIn
.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
Citi 2026 Biopharma Back to School Conference
in New York, NY with a fireside chat on Thursday, September 10, 2026, at 8:40 a.m. ET.
H.C. Wainwright 28th Annual Global Investment Conference
in New York, NY with a fireside chat on Tuesday, September 15, 2026, at 10:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at
www.syndax.com
, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj
®
(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit
www.syndax.com
or follow the Company on
X
and
.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。